- Home
- JAKK vs CHRS Comparison
JAKK vs CHRS Comparison
Compare JAKK & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAKK | CHRS |
|---|---|---|
| Founded | 1995 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.1M | 186.0M |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | JAKK | CHRS |
|---|---|---|
| Price | $16.56 | $1.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $36.67 | $4.51 |
| AVG Volume (30 Days) | 92.0K | ★ 987.2K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 6.06% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.53 | ★ 1.34 |
| Revenue | ★ $574,298,000.00 | $277,728,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.54 | $67.29 |
| P/E Ratio | $31.14 | ★ $1.04 |
| Revenue Growth | N/A | ★ 152.07 |
| 52 Week Low | $14.87 | $0.71 |
| 52 Week High | $35.79 | $1.89 |
Technical Indicators
Market Signals| Indicator | JAKK | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 48.58 | 52.09 |
| Support Level | $16.24 | $1.31 |
| Resistance Level | $16.93 | $1.45 |
| Average True Range (ATR) | 0.51 | 0.09 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 72.57 | 72.29 |
Price Performance
Historical ComparisonAbout JAKK JAKKS Pacific Inc.
Jakks Pacific Inc is a multi-product line, multi-brand toy company that designs, produces, markets, sells and distributes toys and related kid-targeted consumer products, inclusive of kids indoor and outdoor furniture, costumes and various product lines in the sporting goods and home furnishings space. Its products offering include Traditional toys and electronics such as Action figures, Toy vehicles, Dolls and accessories, Ride-on toys, Toys for pets, and others. The company's products have been divided into two segments: (i) Toys/Consumer Products and (ii) Costumes.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.